The effect of deoxyelephantopin enhances doxorubicin sensitivity to mcf-7 cancer cells Frengki1,3,*, Putra Deddi P.2, Wahyuni Fatma Sri2, Khambri Daan1, Sofia Vivi4 1Department of Biomedicine, Faculty of Medicine, Andalas University, Padang, West Sumatera 2Faculty of Pharmacy, Andalas University, Padang, West Sumatera 3Faculty of Veterinary Medicine, Syiah Kuala University, Banda Aceh, Aceh 4Department of Pharmacology and Clinical Pharmacy, Ahmad Dahlan University, Jogjakarta *Corresponding Author E-mail: frengki_fkh@unsyiah.ac.id
Online published on 25 August, 2021. Abstract Deoxyelephantopin is a lactone sesquiterpene compound that shows toxic effects on some cancer cells, otherwise, it is safe on normal cells. The combination of chemotherapy with this compound is intended to determine its effect in increasing the sensitivity of chemotherapy to MCF-7 cancer cells. Cell viability was determined through the MTT method (3-(4,5-dimethyl thiazol-2-il) -2,5-diphenyltetrazolium bromide) to determine the combined effect, while the number of cell deaths was determined through trypan blue staining. Giving deoxyelephantopin-doxorubicin combination to MCF-7 cells showed a synergistic effect with a CI < 0.7. The number of cells that died in the 1.52x and 2.12x combination treatments was higher than the single doxorubicin treatment each at IC50 and/IC50 concentrations, this confirms the synergistic effect of the combination. This research proves that deoxyelephantopin can increase the sensitivity and effectiveness of doxorubicin chemotherapy against MCF-7 breast cancer cells. Top Keywords Deoxyelephantopin, Doxorubicin, Co-Chemotherapy, MCF-7. Top |